Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
申请人:University of Pittsburgh-Of the Commonwealth System of Higher Education
公开号:US10004730B2
公开(公告)日:2018-06-26
A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from:
(a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or
(b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of:
wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group;
R21 is an alkanediyl or a substituted alkanediyl;
a is 0 or 1;
c is 0 or 1;
X is C or S;
R22 is a moiety that includes at least one divalent amino radical; and
R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group.
一种治疗受试者前列腺癌的方法,包括向受试者施用治疗有效量的至少一种制剂,其中所述制剂选自以下物质
(a) 苯基取代咪唑,或其药学上可接受的盐或酯;或
(b) 具有式 I 的化合物或其药学上可接受的盐或酯:
其中 R20 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硅基的基团、含硼酸基的基团、含膦基的基团、氨基、含硫基的基团、含硒基的基团、卤化物或含硝基的基团;
R21 是烷二基或取代的烷二基;
a 是 0 或 1
c 是 0 或 1;
X 是 C 或 S;
R22 是包括至少一个二价氨基的分子;和
R23 是芳基、取代的芳基、杂芳基、取代的杂芳基、杂环烷基、取代的杂环烷基、烷氧基、芳氧基、含硅烷基的基团、含硼酸基的基团、含膦基的基团、氨基、含硫代基的基团、含硒代基的基团、卤化物或含硝基的基团。